LOS ANGELES, May 20, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Senti Biosciences, Inc. ("Senti" or "the Company") (NASDAQ: SNTI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Senti announced in a press release issued on April 28, 2025, that "enrollmen ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Senti Biosciences, Inc. and its officers or directors [1] Group 1: Company Developments - On April 28, 2025, Senti announced the cessation of enrollment in the Investigator Sponsored Trial for its solid tumor pipeline product SN301A due to observed dose limiting toxicities [2] - Following this announcement, Senti's stock price dropped by $1.36 per share, representing a decline of 27.2%, closing at $3.64 per share on the same day [2] Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of advocating for victims of securities fraud and corporate misconduct [3] - The firm has a track record of recovering significant damages for class members, highlighting its expertise in handling such cases [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Senti Biosciences, Inc. and its officers or directors [1] Group 1: Company Developments - On April 28, 2025, Senti announced the cessation of enrollment in the Investigator Sponsored Trial for its solid tumor product SN301A due to observed dose limiting toxicities [3] - Following this announcement, Senti's stock price dropped by $1.36 per share, representing a 27.2% decline, closing at $3.64 per share on the same day [3] Group 2: Legal Actions - Pomerantz LLP is actively seeking claims from investors of Senti Biosciences, indicating a potential class action lawsuit [1][2] - The firm has a long history in corporate, securities, and antitrust class litigation, having recovered significant damages for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Senti Biosciences, Inc. following a significant drop in stock price due to halted clinical trials [1][3]. Group 1: Company Developments - On April 28, 2025, Senti announced the cessation of enrollment in the Investigator Sponsored Trial for its solid tumor product SN301A due to observed dose limiting toxicities [3]. - Following this announcement, Senti's stock price decreased by $1.36 per share, representing a 27.2% decline, closing at $3.64 per share [3]. Group 2: Legal Investigation - Pomerantz LLP is representing investors of Senti and is looking into claims of securities fraud or other unlawful practices by the company and its officers or directors [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action investigation [1].

Core Insights - Senti Biosciences, Inc. presented positive preliminary data for SENTI-202, a potential first-in-class CAR-NK cell therapy for relapsed/refractory AML, at the AACR Annual Meeting 2025 [1][2][3] Clinical Data Summary - The Phase 1 study of SENTI-202 involved 9 patients with relapsed or refractory AML, with 7 evaluable for overall response [3] - The study identified a preliminary recommended Phase 2 dose (RP2D) of 1.5 x 10 CAR NK cells administered on Days 0, 7, and 14 in 28-day cycles [3] - 5 of 7 evaluable patients achieved an overall response rate (ORR), with 4 achieving composite complete remission (cCR) [3][7] - All cCR patients were measurable residual disease (MRD) negative, indicating a strong efficacy profile [3][7] Safety and Tolerability - SENTI-202 was well-tolerated with no dose-limiting toxicities reported, and a maximum tolerated dose was not reached [3][7] - Adverse events were consistent with other investigational NK cell therapies, with no grade 5 adverse events observed [7] Financial Highlights - As of March 31, 2025, Senti Bio held approximately $33.8 million in cash and cash equivalents [13] - Research and development expenses for Q1 2025 were $9.3 million, an increase from $8.8 million in Q1 2024 [13] - The net loss for the quarter was $14.1 million, or $1.41 per share [13] Pipeline Update - The Phase 1 study of SENTI-202 is ongoing, with plans for disease-specific expansion cohorts [4] - Senti Bio is also evaluating SENTI-301A for HCC, but enrollment has been stopped due to observed dose-limiting toxicities [10] Company Overview - Senti Bio is focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][15] - The company aims to engineer therapies that selectively target and eliminate cancer cells while sparing healthy cells [15]

Core Insights - Senti Biosciences, Inc. presented positive preliminary data for SENTI-202, a potential first-in-class CAR-NK cell therapy for relapsed/refractory AML, at the AACR Annual Meeting 2025 [1][2][3] - The Phase 1 study identified a recommended Phase 2 dose (RP2D) of 1.5 x 10^9 CAR NK cells, with no dose limiting toxicities observed [3][4] - The therapy demonstrated a 71% overall response rate (ORR) among evaluable patients, with 4 out of 7 achieving composite complete remission (cCR) [3][5] Clinical Data - The study involved 9 patients treated with SENTI-202, with 7 evaluable for overall response [3] - Efficacy results included 5 of 7 patients achieving ORR, with 3 complete remissions (CR) and 1 CR with partial hematologic recovery (CRh) [3][9] - All cCR patients were found to be measurable residual disease (MRD) negative [3][9] Safety Profile - SENTI-202 was well-tolerated, with an adverse event profile consistent with other investigational NK cell therapies [9] - No grade 5 adverse events were reported, and most grade 3 or higher events were attributed to lymphodepleting chemotherapy rather than SENTI-202 [9] Financial Highlights - As of March 31, 2025, Senti Bio reported cash and cash equivalents of approximately $33.8 million [8] - Research and development expenses for Q1 2025 were $9.3 million, an increase from $8.8 million in Q1 2024 [15] - General and administrative expenses decreased to $7.1 million in Q1 2025 from $7.5 million in Q1 2024 [15] Pipeline Update - The Phase 1 study of SENTI-202 is ongoing, with plans for disease-specific expansion cohorts [4] - Senti Bio is also collaborating on SENTI-301A for hepatocellular carcinoma (HCC), although enrollment has been halted due to dose limiting toxicities observed in a related trial [10]